Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Parkinson's disease medical therapy

Introduction

Overview

Overview

The mainstay of therapy for motor symptoms of Parkinson disease are: Levodopa, dopamine agonists, monoamine oxidase (MAO) B inhibitors, anticholinergic agents, amantadine, catechol-O-methyl transferase (COMT) inhibitors, estrogen and other drugs such as Exenatide, uric acid, isradipine, nilotinib and GDNF infusion.

Treatment choices for some of the nonmotor symptoms of PD are:

psychosis: quetiapine, clozapine and pimavanserin.

Dementia: Cholinesterase inhibitors such as rivastigmine and donepezil.

Fatigue: Amantadine, methylphenidate and pemoline.

Depression: Amitriptyline, desipramine, citalopram ,paroxetine, venlafaxine, ropinirole and pramipexole.

Constipation: Increasing probiotics and fibers, lubiprostone and polyethylene glycol.

Sialorrhea: chewing gum and hard candy but in severe cases, botulinum toxin injection into salivary glands .

Sexual dysfunction: sildenafil (for male)

Ortostatic hypotention: Fludrocortisone, Sympathomimetic agents such as ephedrine, pseudoephedrine, methylphenidate and dextroamphetamine.

Medical Therapy

Medical Therapy

The mainstay of therapy for motor symptoms of Parkinson disease are:

Treatment choices for some of the nonmotor symptoms of PD are:

References

References

  1. ↑ Connolly BS, Lang AE (2014). “Pharmacological treatment of Parkinson disease: a review”. JAMA. 311 (16): 1670–83. doi:10.1001/jama.2014.3654. PMIDΒ 24756517.
  2. ↑ Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, SchΓΌpbach M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH (January 2013). “Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease”. Eur. J. Neurol. 20 (1): 5–15. doi:10.1111/j.1468-1331.2012.03866.x. PMIDΒ 23279439.
  3. ↑ “Parcopa: a rapidly dissolving formulation of carbidopa/levodopa”. Med Lett Drugs Ther. 47 (1201): 12. January 2005. PMIDΒ 15706700.
  4. ↑ Ondo WG, Shinawi L, Moore S (December 2010). “Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial”. Mov. Disord. 25 (16): 2724–7. doi:10.1002/mds.23158. PMIDΒ 20925074.
  5. ↑ Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D (October 2008). “Neuropathy as a potential complication of levodopa use in Parkinson’s disease”. Mov. Disord. 23 (13): 1850–9. doi:10.1002/mds.22137. PMIDΒ 18785232.
  6. ↑ Toth C, Breithaupt K, Ge S, Duan Y, Terris JM, Thiessen A, Wiebe S, Zochodne DW, Suchowersky O (July 2010). “Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease”. Ann. Neurol. 68 (1): 28–36. doi:10.1002/ana.22021. PMIDΒ 20582991.
  7. ↑ Ceravolo R, Cossu G, Bandettini di Poggio M, Santoro L, Barone P, Zibetti M, Frosini D, Nicoletti V, Manganelli F, Iodice R, Picillo M, Merola A, Lopiano L, Paribello A, Manca D, Melis M, Marchese R, Borelli P, Mereu A, Contu P, Abbruzzese G, Bonuccelli U (September 2013). “Neuropathy and levodopa in Parkinson’s disease: evidence from a multicenter study”. Mov. Disord. 28 (10): 1391–7. doi:10.1002/mds.25585. PMIDΒ 23836370.
  8. ↑ Uncini A, Eleopra R, Onofrj M (May 2015). “Polyneuropathy associated with duodenal infusion of levodopa in Parkinson’s disease: features, pathogenesis and management”. J. Neurol. Neurosurg. Psychiatry. 86 (5): 490–5. doi:10.1136/jnnp-2014-308586. PMIDΒ 25168395.
  9. ↑ Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B (November 2010). “Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap”. Lancet Neurol. 9 (11): 1106–17. doi:10.1016/S1474-4422(10)70218-0. PMIDΒ 20880751.
  10. ↑ Aquino CC, Fox SH (January 2015). “Clinical spectrum of levodopa-induced complications”. Mov. Disord. 30 (1): 80–9. doi:10.1002/mds.26125. PMIDΒ 25488260.
  11. ↑ Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Bonucelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F (September 2004). “Levodopa in the treatment of Parkinson’s disease: current controversies”. Mov. Disord. 19 (9): 997–1005. doi:10.1002/mds.20243. PMIDΒ 15372588.
  12. ↑ Rajput AH (2001). “The protective role of levodopa in the human substantia nigra”. Adv Neurol. 86: 327–36. PMIDΒ 11553992.
  13. ↑ Parkkinen L, O’Sullivan SS, KuoppamΓ€ki M, Collins C, Kallis C, Holton JL, Williams DR, Revesz T, Lees AJ (October 2011). “Does levodopa accelerate the pathologic process in Parkinson disease brain?”. Neurology. 77 (15): 1420–6. doi:10.1212/WNL.0b013e318232ab4c. PMIDΒ 21917769.
  14. ↑ Olanow CW, Watts RL, Koller WC (June 2001). “An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines”. Neurology. 56 (11 Suppl 5): S1–S88. PMIDΒ 11402154.
  15. ↑ Fahn S (December 1996). “Is levodopa toxic?”. Neurology. 47 (6 Suppl 3): S184–95. PMIDΒ 8959987.
  16. ↑ “International symposium on early dopamine agonist therapy of Parkinson’s disease”. Arch. Neurol. 45 (2): 204–8. February 1988. PMIDΒ 3341935.
  17. ↑ Marras C, Lang A (May 2008). “Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain”. Neurology. 70 (21): 1996–2003. doi:10.1212/01.wnl.0000312515.52545.51. PMIDΒ 18490620.
  18. ↑ Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, Shah L, Wheatley K, Gray R (April 2008). “Dopamine agonist therapy in early Parkinson’s disease”. Cochrane Database Syst Rev (2): CD006564. doi:10.1002/14651858.CD006564.pub2. PMIDΒ 18425954.
  19. ↑ Roth BL (January 2007). “Drugs and valvular heart disease”. N. Engl. J. Med. 356 (1): 6–9. doi:10.1056/NEJMp068265. PMIDΒ 17202450.
  20. ↑ Olanow CW (December 1996). “Selegiline: current perspectives on issues related to neuroprotection and mortality”. Neurology. 47 (6 Suppl 3): S210–6. PMIDΒ 8959990.
  21. ↑ 21.0 21.1 Horn S, Stern MB (October 2004). “The comparative effects of medical therapies for Parkinson’s disease”. Neurology. 63 (7 Suppl 2): S7–12. PMIDΒ 15477585.
  22. ↑ “A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study”. Arch. Neurol. 59 (12): 1937–43. December 2002. PMIDΒ 12470183.
  23. ↑ “A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease”. Arch. Neurol. 61 (4): 561–6. April 2004. doi:10.1001/archneur.61.4.561. PMIDΒ 15096406.
  24. ↑ Vitale C, Santangelo G, Erro R, Errico D, Manganelli F, Improta I, Moccia M, Barone P (April 2013). “Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson’s disease: report of 2 cases”. Parkinsonism Relat. Disord. 19 (4): 483–4. doi:10.1016/j.parkreldis.2012.11.008. PMIDΒ 23305965.
  25. ↑ Duvoisin RC (August 1967). “Cholinergic-anticholinergic antagonism in parkinsonism”. Arch. Neurol. 17 (2): 124–36. PMIDΒ 4382112.
  26. ↑ Katzenschlager R, Sampaio C, Costa J, Lees A (2003). “Anticholinergics for symptomatic management of Parkinson’s disease”. Cochrane Database Syst Rev (2): CD003735. doi:10.1002/14651858.CD003735. PMIDΒ 12804486.
  27. ↑ Lang AE (February 1984). “Treatment of Parkinson’s disease with agents other than levodopa and dopamine agonists: controversies and new approaches”. Can J Neurol Sci. 11 (1 Suppl): 210–20. PMIDΒ 6143611.
  28. ↑ Schwab RS, Poskanzer DC, England AC, Young RR (November 1972). “Amantadine in Parkinson’s disease. Review of more than two years’ experience”. JAMA. 222 (7): 792–5. PMIDΒ 4677928.
  29. ↑ “Amantadine and other antiglutamate agents: management of Parkinson’s disease”. Mov. Disord. 17 Suppl 4: S13–22. 2002. doi:10.1002/mds.5557. PMIDΒ 12211136.
  30. ↑ Parkes JD, Baxter RC, Marsden CD, Rees JE (April 1974). “Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson’s disease”. J. Neurol. Neurosurg. Psychiatry. 37 (4): 422–6. PMCΒ 494673. PMIDΒ 4838913.
  31. ↑ Nutt JG (April 1998). “Catechol-O-methyltransferase inhibitors for treatment of Parkinson’s disease”. Lancet. 351 (9111): 1221–2. doi:10.1016/S0140-6736(05)79311-9. PMIDΒ 9643737.
  32. ↑ Brooks DJ, Sagar H (August 2003). “Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study”. J. Neurol. Neurosurg. Psychiatry. 74 (8): 1071–9. PMCΒ 1738605. PMIDΒ 12876237.
  33. ↑ Tsang KL, Ho SL, Lo SK (June 2000). “Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations”. Neurology. 54 (12): 2292–8. PMIDΒ 10881255.
  34. ↑ Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S (April 1999). “The effect of estrogen replacement on early Parkinson’s disease”. Neurology. 52 (7): 1417–21. PMIDΒ 10227628.
  35. ↑ Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS (May 2008). “Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson’s disease”. J Neuroinflammation. 5: 19. doi:10.1186/1742-2094-5-19. PMCΒ 2426681. PMIDΒ 18492290.
  36. ↑ Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA (December 2009). “Urate as a predictor of the rate of clinical decline in Parkinson disease”. Arch. Neurol. 66 (12): 1460–8. doi:10.1001/archneurol.2009.247. PMCΒ 2795011. PMIDΒ 19822770.
  37. ↑ Ilijic E, Guzman JN, Surmeier DJ (August 2011). “The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson’s disease”. Neurobiol. Dis. 43 (2): 364–71. doi:10.1016/j.nbd.2011.04.007. PMCΒ 3235730. PMIDΒ 21515375.
  38. ↑ Wyse RK, Brundin P, Sherer TB (July 2016). “Nilotinib – Differentiating the Hope from the Hype”. J Parkinsons Dis. 6 (3): 519–22. doi:10.3233/JPD-160904. PMCΒ 5044778. PMIDΒ 27434298.
  39. ↑ Gill SS, Patel NK, Hotton GR, O’Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P (May 2003). “Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease”. Nat. Med. 9 (5): 589–95. doi:10.1038/nm850. PMIDΒ 12669033.
  40. ↑ Shotbolt P, Samuel M, David A (November 2010). “Quetiapine in the treatment of psychosis in Parkinson’s disease”. Ther Adv Neurol Disord. 3 (6): 339–50. doi:10.1177/1756285610389656. PMCΒ 3002640. PMIDΒ 21179595.
  41. ↑ Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C (February 2014). “Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial”. Lancet. 383 (9916): 533–40. doi:10.1016/S0140-6736(13)62106-6. PMIDΒ 24183563.
  42. ↑ Schulte P (April 2006). “Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring”. Ann Pharmacother. 40 (4): 683–8. doi:10.1345/aph.1G396. PMIDΒ 16595571.
  43. ↑ Rolinski M, Fox C, Maidment I, McShane R (March 2012). “Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease”. Cochrane Database Syst Rev (3): CD006504. doi:10.1002/14651858.CD006504.pub2. PMIDΒ 22419314.
  44. ↑ Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R (December 2004). “Rivastigmine for dementia associated with Parkinson’s disease”. N. Engl. J. Med. 351 (24): 2509–18. doi:10.1056/NEJMoa041470. PMIDΒ 15590953.
  45. ↑ Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, Pourcher E, Gray J, Thomas G, Swartz J, Hsu T, Moline ML (September 2012). “Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study”. Mov. Disord. 27 (10): 1230–8. doi:10.1002/mds.25098. PMIDΒ 22915447.
  46. ↑ Elbers RG, Verhoef J, van Wegen EE, Berendse HW, Kwakkel G (October 2015). “Interventions for fatigue in Parkinson’s disease”. Cochrane Database Syst Rev (10): CD010925. doi:10.1002/14651858.CD010925.pub2. PMIDΒ 26447539.
  47. ↑ MendonΓ§a DA, Menezes K, Jog MS (October 2007). “Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial”. Mov. Disord. 22 (14): 2070–6. doi:10.1002/mds.21656. PMIDΒ 17674415.
  48. ↑ Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, Miyasaki J, Iverson DJ, Weiner WJ (March 2010). “Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology”. Neurology. 74 (11): 924–31. doi:10.1212/WNL.0b013e3181d55f24. PMIDΒ 20231670.
  49. ↑ Serrano-DueΓ±as M (2002). “[A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson’s disease]”. Rev Neurol (in Spanish; Castilian). 35 (11): 1010–4. PMIDΒ 12497304.
  50. ↑ Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, DestΓ©e A, Bordet R, Defebvre L (April 2008). “Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study”. Mov. Disord. 23 (6): 850–7. doi:10.1002/mds.21966. PMIDΒ 18311826.
  51. ↑ Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W (April 2012). “A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease”. Neurology. 78 (16): 1229–36. doi:10.1212/WNL.0b013e3182516244. PMCΒ 3324323. PMIDΒ 22496199.
  52. ↑ 52.0 52.1 Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (October 2011). “The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease”. Mov. Disord. 26 Suppl 3: S42–80. doi:10.1002/mds.23884. PMCΒ 4020145. PMIDΒ 22021174.
  53. ↑ Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL (April 2007). “Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease”. Neurology. 68 (14): 1108–15. doi:10.1212/01.wnl.0000258660.74391.c1. PMIDΒ 17404192.
  54. ↑ Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D (June 2010). “Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial”. Lancet Neurol. 9 (6): 573–80. doi:10.1016/S1474-4422(10)70106-X. PMIDΒ 20452823.
  55. ↑ Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner WJ (April 2006). “Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology”. Neurology. 66 (7): 996–1002. doi:10.1212/01.wnl.0000215428.46057.3d. PMIDΒ 16606910.
  56. ↑ Bharucha KJ, Sethi KD (May 1996). “Complex movement disorders induced by fluoxetine”. Mov. Disord. 11 (3): 324–6. doi:10.1002/mds.870110318. PMIDΒ 8723152.
  57. ↑ Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C (April 1997). “Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Parkinson Study Group”. Neurology. 48 (4): 1070–7. PMIDΒ 9109902.
  58. ↑ Ondo WG, Kenney C, Sullivan K, Davidson A, Hunter C, Jahan I, McCombs A, Miller A, Zesiewicz TA (May 2012). “Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease”. Neurology. 78 (21): 1650–4. doi:10.1212/WNL.0b013e3182574f28. PMIDΒ 22573627.
  59. ↑ Zangaglia R, Martignoni E, Glorioso M, Ossola M, Riboldazzi G, Calandrella D, Brunetti G, Pacchetti C (July 2007). “Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study”. Mov. Disord. 22 (9): 1239–44. doi:10.1002/mds.21243. PMIDΒ 17566120.
  60. ↑ Barichella M, Pacchetti C, Bolliri C, Cassani E, Iorio L, Pusani C, Pinelli G, Privitera G, Cesari I, Faierman SA, Caccialanza R, Pezzoli G, Cereda E (September 2016). “Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT”. Neurology. 87 (12): 1274–80. doi:10.1212/WNL.0000000000003127. PMIDΒ 27543643.
  61. ↑ Pfeiffer RF (January 2011). “Gastrointestinal dysfunction in Parkinson’s disease”. Parkinsonism Relat. Disord. 17 (1): 10–5. doi:10.1016/j.parkreldis.2010.08.003. PMIDΒ 20829091.
  62. ↑ Cloud LJ, Greene JG (August 2011). “Gastrointestinal features of Parkinson’s disease”. Curr Neurol Neurosci Rep. 11 (4): 379–84. doi:10.1007/s11910-011-0204-0. PMIDΒ 21499704.
  63. ↑ Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L (February 2012). “Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson’s disease: a prospective double-blind trial”. Mov. Disord. 27 (2): 219–26. doi:10.1002/mds.23929. PMIDΒ 21887710.
  64. ↑ Raffaele R, Vecchio I, Giammusso B, Morgia G, Brunetto MB, Rampello L (April 2002). “Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson’s disease”. Eur. Urol. 41 (4): 382–6. PMIDΒ 12074807.
  65. ↑ Campbell IW, Ewing DJ, Clarke BF (April 1975). “9-Alpha-fluorohydrocortisone in the treatment of postural hypotension in diabetic autonomic neuropathy”. Diabetes. 24 (4): 381–4. PMIDΒ 1094320.
  66. ↑ Davies B, Bannister R, Sever P (January 1978). “Pressor amines and monoamine-oxidase inhibitors for treatment of postural hypotension in autonomic failure. Limitations and hazards”. Lancet. 1 (8057): 172–5. PMIDΒ 74603.
  67. ↑ Biaggioni I, Onrot J, Stewart CK, Robertson D (July 1987). “The potent pressor effect of phenylpropanolamine in patients with autonomic impairment”. JAMA. 258 (2): 236–9. PMIDΒ 3599310.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]